Pemigatinib Demonstrates Activity in Previously Treated Solid Tumors Harboring Activating FGFR Alterations

Pemigatinib generated efficacy and tolerability in previously treated patients with advanced/metastatic or unresectable solid tumors harboring activating FGFR mutations or fusions/rearrangements, including cholangiocarcinoma, central nervous system tumors, gynecologic tumors, and pancreatic cancer.

Related Keywords

Black Diamond ,Texas ,United States ,Hebron ,Israel General ,Israel ,Houston ,Nuvation Bio ,Pemigatinib Pemazyre ,Hutchison Medipharma ,Yingli Pharma ,Chinese University Of Hong Kong ,Amgen ,Pfizer ,Department Of Investigational Cancer Therapeutics ,Novartis ,Foundation Medicine Inc ,University Of Texas Md Anderson Cancer Center ,Pharma Group ,Spectrum Pharmaceuticals ,Debiopharm Group ,Glaxosmithkline ,Division Of Cancer Medicine ,Hebron Institute Of Oncology ,Jordi Rod ,Investigational Cancer Therapeutics ,Cancer Medicine ,Cancer Center ,Response Assessment ,Foundation Medicine ,Ellipses Pharma ,Monte Rosa Therapeutics ,Oncology One ,Sardona Therapeutics ,Hebron Institute ,Avoro Capital Advisors ,Boxer Capital ,Chinese University ,Hong Kong ,Clarion Healthcare ,Columbus Venture Partners ,Envision Pharma Group ,Tang Advisors ,Black Diamond Therapeutics ,Blueprint Medicines ,Merck Sharp ,Bicycle Therapeutics ,Biomed Valley Discoveries ,Cellestia Biotech ,Cytomx Therapeutics ,Linnaeus Therapeutics ,Mirati Therapeutics ,Taiho Pharmaceutical ,Pemigatinib ,Previously Treated Patients With Advanced Metastatic Or Unresectable Solid Tumors ,Activating Fgfr Mutations Or Fusions Rearrangements ,Cholangiocarcinoma ,Central Nervous System Tumors ,Gynecologic Tumors ,Pancreatic Cancer ,Fight 207 Trial ,Nct03822117 ,Eudract 2018 004768 69 ,Jordi Rodón ,D ,Phd ,The University Of Texas Md Anderson Cancer Center ,